keyword
MENU ▼
Read by QxMD icon Read
search

Sirolimus v everolimus

keyword
https://www.readbyqxmd.com/read/27468645/intra-cellular-immunosuppressive-drugs-monitoring-a-step-forward-towards-better-therapeutic-efficacy-after-organ-transplantation
#1
REVIEW
A Capron, V Haufroid, P Wallemacq
Immunosuppressive drugs (IS) used in solid organ transplantation are critical dose drugs with high intra- and inter-subject variability. Therefore, IS therapeutic drug monitoring (TDM), mainly as trough levels analysis, is a major support to patient management, mandatory to optimize clinical outcome. Even though transplant patients undoubtedly benefited by this pre-dose (C0) monitoring, the relationship between these C0 concentrations and the incidence of graft rejections remains hardly predictable. Identification and validation of additional biomarkers of efficacy are therefore very much needed...
September 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27116326/duration-of-dual-antiplatelet-therapy-after-various-drug-eluting-stent-implantation
#2
Abhishek Sharma, Samin K Sharma, Ajay Vallakati, Akash Garg, Carl J Lavie, Debabrata Mukherjee, Jonathan D Marmur
OBJECTIVE: To evaluate efficacy and safety of long duration dual anti-platelet therapy i.e., >12months (L-DAPT) and short duration DAPT i.e., ≤12months (S-DAPT) after various drug-eluting stent (DES) implantation. METHODS: We searched Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials (RCTs) assessing the effect of L-DAPT versus S-DAPT after sirolimus-eluting (Cypher®); paclitaxel-eluting stents (Taxus®); zotarolimus-eluting (Endeavor®) and everolimus-eluting stents (Xience V®) implantation...
July 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/26892409/safety-and-efficacy-of-everolimus-versus%C3%A2-sirolimus-eluting-stents-5-year-results-from-sort-out-iv
#3
Lisette Okkels Jensen, Per Thayssen, Evald Høj Christiansen, Michael Maeng, Jan Ravkilde, Knud Nørregaard Hansen, Henrik Steen Hansen, Lars Krusell, Anne Kaltoft, Hans Henrik Tilsted, Klara Berencsi, Anders Junker, Jens Flensted Lassen
BACKGROUND: Long-term safety and efficacy for everolimus-eluting stents (EES) versus those of sirolimus-eluting stents (SES) are unknown. OBJECTIVES: This study compared 5-year outcomes for EES with those for SES from the SORT OUT IV (Scandinavian Organization for Randomized Trials with Clinical Outcome) trial. METHODS: Five-year follow-up was completed for 2,771 patients (99.9%). Primary endpoint was a composite of major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), and definite stent thrombosis...
February 23, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/26604019/-pulmonary-lymphangioleiomyomatosis-from-pathogenesis-to-management
#4
N Chebib, C Khouatra, R Lazor, F Archer, C Leroux, D Gamondes, F Thivolet-Bejui, J F Cordier, V Cottin
INTRODUCTION: Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease affecting mainly young women. BACKGROUND: The respiratory manifestations are characterized by a progressive cystic destruction of the lung parenchyma. Extrapulmonary involvement includes benign renal tumours called angiomyolipomas and abdominal lymphatic masses called lymphangioleiomyomas. At the pathological level, the cellular proliferation found in LAM is in part due to the presence of mutations in the tumour suppressor genes TSC1 and TSC2 (Tuberous Sclerosis Complex)...
November 18, 2015: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/26291980/impact-of-laboratory-practices-on-interlaboratory-variability-in-therapeutic-drug-monitoring-of-immunosuppressive-drugs
#5
Uwe Christians, Alexander A Vinks, Loralie J Langman, William Clarke, Pierre Wallemacq, Teun van Gelder, Varun Renjen, Pierre Marquet, Eric J Meyer
The immunosuppressants cyclosporine, tacrolimus, sirolimus, everolimus, and probably also mycophenolic acid require therapeutic drug monitoring (TDM)-guided dosing to ensure that blood concentrations are kept within the target range in transplant patients. Reliable, accurate, and precise test methods are therefore essential to effectively monitor levels and to make proper dose adjustments. Data from proficiency testing programs have shown substantial interlaboratory variability. Only few attempts have been made to study the underlying causes...
December 2015: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/26268482/comparison-of-sirolimus-eluting-stent-with-bioresorbable-polymer-to-everolimus-eluting-stent-with-permanent-polymer-in-bifurcation-lesions-results-from-century-ii-trial
#6
K Orvin, D Carrie, G Richardt, W Desmet, A Assali, G Werner, Y Ikari, K Fujii, J Goicolea, V Dangoisse, A Manari, S Saito, W Wijns, R Kornowski
OBJECTIVE: To demonstrate the safety and efficacy of a new sirolimus eluting stent with bioresorbable polymer, Ultimaster, (BP-SES) compared with everolimus-eluting, permanent polymer, Xience stent (PP-EES) in bifurcation lesions with respect to the freedom from Target Lesion Failure at 1-year. METHODS: Within 1,119 patients enrolled in the CENTURY II randomized controlled multicenter trial, 194 patients were treated for bifurcation lesions and randomized to either BP-SES (n = 95) or PP-EES (n = 99)...
May 2016: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/26033073/long-term-outcomes-with-first-vs-second-generation-drug-eluting-stents-in-saphenous-vein-graft-lesions
#7
Nagendra R Pokala, Rohan V Menon, Siddharth M Patel, George Christopoulos, Georgios E Christakopoulos, Anna P Kotsia, Bavana V Rangan, Michele Roesle, Shuaib Abdullah, Jerrold Grodin, Dharam J Kumbhani, Jeffrey Hastings, Subhash Banerjee, Emmanouil S Brilakis
BACKGROUND: As compared with bare metal stents, first-generation drug-eluting stents (DES) improved post-procedural outcomes in aortocoronary saphenous vein graft (SVG) lesions, but there is limited information on outcomes after use of second-generation DES in SVGs. METHODS: We compared the outcomes of patients who received first- (n = 81) with those who received second-generation (n = 166) DES in SVG lesions at our institution between 2006 and 2013. Major adverse cardiac events (MACE) were defined as the composite of all-cause death, myocardial infarction, and target vessel revascularization...
January 1, 2016: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/25744629/characterization-of-patients-with-angioscopically-detected-in-stent-mural-thrombi-%C3%A2-genetics-of-clopidogrel-responsiveness-and-generations-of-drug-eluting-stents
#8
COMPARATIVE STUDY
Minoru Ichikawa, Yoshizumi Takei, Toshimitsu Hamasaki, Yoshiyuki Kijima
BACKGROUND: The loss-of-function genotype of cytochrome P450 2C19 (CYP2C19) has been proposed as a risk factor for stent thrombosis in patients with drug-eluting stent implantation. The aim of this study was to clarify the clinical features of patients with angioscopically-detected in-stent mural thrombi (ISMT). METHODS AND RESULTS: Enrolled were 100 stented segments in 55 patients with stable angina (20 bare-metal stents; 39 Cypher sirolimus-eluting stents [SES]; 26 Endeavor zotarolimus-eluting stents [ZES]; 13 Xience V everolimus-eluting stents; and 2 Nobori biolimus-eluting stents)...
2015: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/25598992/coronary-vasomotion-dysfunction-after-everolimus-eluting-stent-implantation
#9
Pietro Giudice, Tiziana Attisano, Marco Di Maio, Elisabetta M Bellino, Maria V Polito, Cesare Baldi, Francesco Vigorito, Michele R Di Muro, Salvatore D Tomasello, Alfredo R Galassi, Federico Piscione
First generation drug-eluting stent can cause a paradoxical "in-segment" coronary vasoconstriction. This phenomenon was seen with sirolimus, paclitaxel, and, more recently, also with zotarolimus-eluting stent. For the first time, we describe a case of coronary-induced vasoconstriction by everolimus-eluting stents (EES).
December 2014: Interventional Medicine & Applied Science
https://www.readbyqxmd.com/read/25531195/lung-injury-associated-with-mtor-inhibitors-sirolimus-and-everolimus
#10
LETTER
V Conti, M Grazia, M Romagnoli, G Poletti, S Cristino, G Ciliberti, S Piciucchi, G Mosconi, V Poletti
No abstract text is available yet for this article.
December 2014: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/25497250/three-year-clinical-outcome-of-patients-with-bifurcation-treatment-with-second-generation-resolute-and-xience-v-stents-in-the-randomized-twente-trial
#11
RANDOMIZED CONTROLLED TRIAL
Ming Kai Lam, Hanim Sen, K Gert van Houwelingen, Marije M Löwik, Liefke C van der Heijden, Marlies M Kok, Frits H A F de Man, Gerard C M Linssen, Kenneth Tandjung, Carine J M Doggen, Clemens von Birgelen
BACKGROUND: Only limited data from large randomized clinical trials have been published on the long-term performance of second-generation drug-eluting stents in bifurcation lesions. METHODS: We investigated in patients in the randomized TWENTE trial the long-term safety and efficacy of treating bifurcation lesions with 2 widely applied second-generation drug-eluting stents, the zotarolimus-eluting Resolute stent (Medtronic Inc, Santa Rosa, CA) and the everolimus-eluting Xience V stent (Abbott Vascular, Santa Clara, CA)...
January 2015: American Heart Journal
https://www.readbyqxmd.com/read/25464603/-twelve-months-results-of-percutaneous-coronary-interventions-in-patients-with-ischemic-heart-disease-combined-with-diabetes-mellitus-using-sirolimus-and-everolimus-covered-stents
#12
COMPARATIVE STUDY
R S Poliakov, Iu M Saakian, G V Mardanian, M V Puretskiĭ, A A Pirkova, A V Boltenkov, S M Naumov, S A Abugov
We included into this study 112 patients with ischemic heart disease (IHD) and concomitant type 2 diabetes mellitus (DM) subjected to percutaneous coronary interventions with stenting. Everolimus and sirolimus eluting stents (EES and SES) were implanted in 54 (group 1) and 58 (group 2) patients, respectively. After 12 months in groups 1 and 2 rates of repeat target lesion revascularizations (TLR) were 5.5 and 8.6% (odds ratio - OR - 0.62, 95% confidence interval - CI - 0.14- 2.74, p = 0.72); acute myocardial infarctions (MI) - 3...
2014: Kardiologiia
https://www.readbyqxmd.com/read/25378023/effects-of-cobalt-chromium-everolimus-eluting-stents-or-bare-metal-stent-on-fatal-and-non-fatal-cardiovascular-events-patient-level-meta-analysis
#13
COMPARATIVE STUDY
Marco Valgimigli, Manel Sabaté, Christoph Kaiser, Salvatore Brugaletta, Jose Maria de la Torre Hernandez, Soeren Galatius, Angel Cequier, Franz Eberli, Adam de Belder, Patrick W Serruys, Giuseppe Ferrante
OBJECTIVES: To examine the safety and effectiveness of cobalt-chromium everolimus eluting stents compared with bare metal stents. DESIGN: Individual patient data meta-analysis of randomised controlled trials. Cox proportional regression models stratified by trial, containing random effects, were used to assess the impact of stent type on outcomes. Hazard ratios with 95% confidence interval for outcomes were reported. DATA SOURCES AND STUDY SELECTION: Medline, Embase, the Cochrane Central Register of Controlled Trials...
2014: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/25354550/characterization-of-patients-with-angioscopically-detected-in-stent-mural-thrombi
#14
Minoru Ichikawa, Yoshizumi Takei, Toshimitsu Hamasaki, Yoshiyuki Kijima
Background:The loss-of-function genotype of cytochrome P450 2C19 (CYP2C19) has been proposed as a risk factor for stent thrombosis in patients with drug-eluting stent implantation. The aim of this study was to clarify the clinical features of patients with angioscopically-detected in-stent mural thrombi (ISMT).Methods and Results:Enrolled were 100 stented segments in 55 patients with stable angina (20 bare-metal stents; 39 Cypher sirolimus-eluting stents [SES]; 26 Endeavor zotarolimus-eluting stents [ZES]; 13 Xience V everolimus-eluting stents; and 2 Nobori biolimus-eluting stents)...
October 30, 2014: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/25219824/synergistic-in-vitro-anti-tumor-effect-of-letrozole-and-everolimus-on-human-endometrial-carcinoma-ishikawa-cells
#15
X-Y Lu, Y Yang, H Xu, T Zeng, Z-Z Zhang
OBJECTIVES: To investigate the in vitro effect of the use of combination of letrozole and everolimus on the proliferation and apoptosis of human endometrial carcinoma Ishikawa cells. MATERIALS AND METHODS: Different concentrations of letrozole alone or in combination with everolimus were added to Ishikawa cell cultures in vitro. Cell viability was assessed using MTT assay. Double staining with Annexin-V-FITC was used to detect the cell apoptosis by the flow cytometry (FCM)...
August 2014: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/25217457/three-year-patient-related-and-stent-related-outcomes-of-second-generation-everolimus-eluting-xience-v-stents-versus-zotarolimus-eluting-resolute-stents-in-real-world-practice-from-the-multicenter-prospective-excellent-and-resolute-korea-registries
#16
RANDOMIZED CONTROLLED TRIAL
Joo Myung Lee, Kyung Woo Park, Jung-Kyu Han, Han-Mo Yang, Hyun-Jae Kang, Bon-Kwon Koo, Jang-Whan Bae, Sung-Il Woo, Jin Sik Park, Dong-Kyu Jin, Dong Woon Jeon, Seok Kyu Oh, Jong-Seon Park, Doo-Il Kim, Min Su Hyon, Hui-Kyung Jeon, Do-Sun Lim, Myeong-Gon Kim, Seung-Woon Rha, Sung-Ho Her, Jin-Yong Hwang, Sanghyun Kim, Young Jin Choi, Jin Ho Kang, Keon-Woong Moon, Yangsoo Jang, Hyo-Soo Kim
Long-term outcomes are imperative to confirm safety of drug-eluting stents. There have been 2 randomized controlled trials comparing everolimus-eluting stents (EESs) and Resolute zotarolimus-eluting stents (ZES-Rs). To date, long-term clinical outcomes of these stents were limited to only 1 report, which has recently reported 4-year comparisons of these stents. Therefore, more evidence is needed regarding long-term clinical outcomes of the second-generation stents. This study compared the long-term clinical outcomes of EES with ZES-R in "all-comer" cohorts up to 3-year follow-up...
November 1, 2014: American Journal of Cardiology
https://www.readbyqxmd.com/read/25146383/risk-of-metabolic-complications-in-kidney-transplantation-after-conversion-to-mtor-inhibitor-a-systematic-review-and-meta-analysis
#17
REVIEW
N Murakami, L V Riella, T Funakoshi
Mammalian target of rapamycin (mTOR) inhibitors have been used in transplantation with the hope of minimizing calcineurin inhibitor (CNI)-induced nephrotoxicity. However, mTOR inhibitors are also associated with a range of side effects, including metabolic complications. We aimed to determine the risks of metabolic complications after the conversion from CNI to mTOR inhibitor postkidney transplant. A systematic search in PubMed up to September 2013 identified nine relevant trials (a total of 2323 patients)...
October 2014: American Journal of Transplantation
https://www.readbyqxmd.com/read/25093491/inhibition-of-hedgehog-signalling-by-nvp-lde225-erismodegib-interferes-with-growth-and-invasion-of-human-renal-cell-carcinoma-cells
#18
C D'Amato, R Rosa, R Marciano, V D'Amato, L Formisano, L Nappi, L Raimondo, C Di Mauro, A Servetto, F Fulciniti, A Cipolletta, C Bianco, F Ciardiello, B M Veneziani, S De Placido, R Bianco
BACKGROUND: Multiple lines of evidence support that the Hedgehog (Hh) signalling has a role in the maintenance and progression of different human cancers. Therefore, inhibition of the Hh pathway represents a valid anticancer therapeutic approach for renal cell carcinoma (RCC) patients. NVP-LDE225 is a Smoothened (Smo) antagonist that induces dose-related inhibition of Hh and Smo-dependent tumour growth. METHODS: We assayed the effects of NVP-LDE225 alone or in combination with everolimus or sunitinib on the growth and invasion of human RCC models both in vitro and in vivo...
September 9, 2014: British Journal of Cancer
https://www.readbyqxmd.com/read/25041227/everolimus-initiation-and-early-calcineurin-inhibitor-withdrawal-in-heart-transplant-recipients-a-randomized-trial
#19
RANDOMIZED CONTROLLED TRIAL
A K Andreassen, B Andersson, F Gustafsson, H Eiskjaer, G Radegran, E Gude, K Jansson, D Solbu, V Sigurdardottir, S Arora, G Dellgren, L Gullestad
In a randomized, open-label trial, everolimus was compared to cyclosporine in 115 de novo heart transplant recipients. Patients were assigned within 5 days posttransplant to low-exposure everolimus (3–6 ng/mL) with reduced-exposure cyclosporine (n = 56), or standard-exposure cyclosporine (n = 59), with both mycophenolate mofetil and corticosteroids. In the everolimus group, cyclosporine was withdrawn after 7–11 weeks and everolimus exposure increased (6–10 ng/mL). The primary efficacy end point, measured GFR at 12 months posttransplant, was significantly higher with everolimus versus cyclosporine (mean ± SD: 79...
August 2014: American Journal of Transplantation
https://www.readbyqxmd.com/read/24981410/-concurrent-association-of-reirradiation-therapy-with-everolimus-for-lymph-node-metastasis-of-gastroesophageal-junction-cancer-a-case-report
#20
V Pernin, P Beuzeboc, D Peurien, C Louvet, Y Kirova
Advanced gastric cancer or gastro-oesophageal junction cancer after a failure of first line chemotherapy have poor outcome. Hereby, we present the first patient treated by radiotherapy with concurrent everolimus, a mTor inhibitor, for a reirradiation of metastasis invading left axillary, infraclavicular and supraclavicular lymph nodes in progression despite several lines of chemotherapy. After 6 months of follow-up, this association provided a satisfactory anti-tumor efficiency and tolerance. Nevertheless, clinical trials are needed in order to confirm this strategy for the treatment of gastric cancer metastasis...
November 2014: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
keyword
keyword
63731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"